Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. - Wikidata - wikimedia - TriplyDB

Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.

Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.

http://www.wikidata.org/entity/Q46168302

about

Treatment of early uterine sarcomas: disentangling adjuvant modalities Adjuvant treatment after hysterectomy for uterine leiomyosarcoma Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement UK guidelines for the management of soft tissue sarcomas Uterine fibroids: current perspectives Unusual indolent behavior of leiomyosarcoma of the vagina: Is observation a viable option?Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors.Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials.Unusually young age distribution of primary hepatic leiomyosarcoma: case series and review of the adult literature Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS).Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Uterine sarcoma. Clinico-pathological characteristics and outcome.A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma.Extragenital adenosarcoma: a case report, review of the literature, and management discussion.Long Term Prognostic Implications of Expression of Glucose Transporter-1 and Hexokinase II in Patients with Stage I Uterine Leiomyosarcoma.Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015).Clinical Characteristics, Surgical Management and Adjuvant Therapy of Patients with Uterine Leiomyosarcoma: 27 Years of Experience The role of adjuvant therapy in uterine leiomyosarcoma A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma.Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors Improved clinical trial enrollments for uterine leiomyosarcoma patients after gynecologic oncology partnership with a sarcoma center Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines.A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients.Role of chemotherapy in the management of soft tissue sarcomas.Histology-driven chemotherapy in soft tissue sarcomas.Treating soft tissue sarcomas with adjuvant chemotherapy.Current management of uterine sarcomas.Diagnosis and management of leiomyosarcoma arising from ovarian vein: case report and literature review.A review of treatment of uterine leiomyosarcomas.Pharmacological treatment for uterine leiomyosarcomas.The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma.Gastrointestinal (GI) leiomyosarcoma (LMS) case series and review on diagnosis, management, and prognosis.Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey.Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome.Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas.Comparison of polyvinyl alcohol and tris-acryl gelatin microsphere materials in embolization for symptomatic leiomyomas: a systematic review.

P2860

Q21245577-4BD79503-C72C-412C-8AD6-0985E905918A Q24187806-BA5AABB3-9FE8-4144-82C2-BB418E047963 Q26767435-58B58737-C46A-4953-A17B-A4957B80855B Q28069514-0C9677EC-F2C8-4F5A-934A-98BC7B7D7C3F Q28076730-B94AFCC4-D359-4F33-BDD8-322EE104A8D3 Q30443242-0FD56243-ED89-4DA7-9E0E-1CD46E6E83A5 Q33802851-3114FDC6-6A0A-414E-A715-D44797DEE4F5 Q33890085-1A38CAFA-6F94-4DD3-9AC4-8A7E438143C3 Q33891037-14F7DD87-8C44-4301-A073-7BD216DAFA03 Q33986704-14AA6900-32C9-4D34-8B56-A3807837B27C Q34045393-90ACC5AC-225F-4C28-B045-A160A0249C9E Q34566745-7A1F0EC2-8A46-42E2-9055-6828C616A8F6 Q34647409-970C41BF-BD92-4BE7-BA8F-432F5A19BDC7 Q34664479-45CE5757-8B8C-4EE9-BC66-C727DDFA1445 Q35183504-70A3CF96-8D57-4D68-A0FA-FA91914234DE Q35616803-2A8CBB5E-C9E7-4F58-AE34-3584A63B1EC3 Q35671534-773B7FE1-1CD2-4149-B21D-F871D6F07F55 Q36001482-0948EAC9-894C-48EF-BDCA-BC3E32FC6672 Q36295510-77C043F6-6E44-40B4-9FBA-AA9659FE2688 Q36743296-D2238CEC-5B8B-4E03-8D3E-8E2DD3E32420 Q36811788-1F9CFDD6-21ED-4601-9A3C-3078ACFDA9D0 Q36826881-0E709C9C-36EE-480A-898C-6361DC144A98 Q36855589-9811A76B-26AF-4714-BDD0-EAFBC80692D3 Q36883521-22314402-B0F1-4A45-A184-CC19C0A22474 Q36929175-98B8183F-F0A2-48F0-BDB9-2C278CACD9DA Q37296303-83051FC4-9222-42CA-85A0-C43E0571C4F0 Q37487765-25882867-874A-4B2B-A79C-0A289B7D5210 Q37687389-4F02CB2E-FC21-42EF-B103-6F510BA2A915 Q37848174-0632E633-D932-4C12-A404-90F5EE7190AF Q37850703-2611D3FE-C47E-4C10-A75D-074FAB8C3936 Q37877412-870E4A70-1BBB-4726-B445-A71E48A6D534 Q37974320-1490EA06-8C8C-4D28-9D9A-782B5D174534 Q38153648-7513F210-7946-41FD-96DC-90E4005DEB2C Q38270671-F65250EC-1DA9-4B6B-968C-CF60DCFF61BF Q38315670-20AFC894-ED9A-469F-A042-F143F1E20AAB Q38703103-289521AE-869C-48ED-B006-8CA448D0FBE6 Q38758661-597F58E5-BB06-4BFA-9987-36710CB009CD Q38765107-306B3674-9566-4B80-99DD-ED1193E552E0 Q38840133-E066C53D-EDAB-4E31-8D58-B73023A3A385 Q38902066-B71F45F7-166E-489F-9A8D-9FD7109EE1BA

P2860

Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.

http://www.wikidata.org/entity/Q46168302

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Adjuvant gemcitabine plus doce ...... esults of a prospective study.

@en

Adjuvant gemcitabine plus doce ...... esults of a prospective study.

@nl

type

label

Adjuvant gemcitabine plus doce ...... esults of a prospective study.

@en

Adjuvant gemcitabine plus doce ...... esults of a prospective study.

@nl

prefLabel

Adjuvant gemcitabine plus doce ...... esults of a prospective study.

@en

Adjuvant gemcitabine plus doce ...... esults of a prospective study.

@nl

P1433

Q46168302-6B6A5986-A0CC-43E6-A118-C56AB0143D64

P1476

Q46168302-660C010E-9C87-459E-8D4A-26016DFB7B1D

P2093

Q46168302-2229B1F0-7D58-4610-AFE8-A74CB89DA43C

Q46168302-412716AA-4E75-470E-8B31-5AC5710B2A7A

Q46168302-4D3C4E6E-021E-465D-A871-6077FEAAC518

Q46168302-6D11544B-127B-4E1D-9DAA-5B20A902C940

Q46168302-A116A7FE-17F3-414A-B91D-C4B6A6BC4F2E

Q46168302-AB39FC51-F27C-4598-898B-B77A29E2DC36

Q46168302-C9FB4EDA-62D8-42A1-B30D-7C21D81D78A5

Q46168302-FE022481-1997-4BF3-BD83-D0C29FC5FF19

P304

Q46168302-5035BE82-90DF-4AA6-8FCA-3CBFEA35F110

P31

Q46168302-10605EF6-C8CE-484D-88BE-581D3150A58F

P356

Q46168302-5F027047-6BEC-4A49-996B-C4ECFFA4F1CC

P407

Q46168302-2F242BF4-20C9-49FF-9207-6DA373A99C40

P433

Q46168302-B9715D3A-11CE-4194-8AC7-8AB0FD3BA1F2

P478

Q46168302-89A47D46-7ED6-433E-93F9-0C1825BEFF0D

P50

Q46168302-43D2BF1D-4BA2-4682-85E4-E5C9F0E51EBF

Q46168302-9B6F33EB-AD3C-4DB3-B245-08C8075759F0

P577

Q46168302-4D9D000B-FA6B-4BDA-AA3E-DF9942ECF01B

P698

Q46168302-F4B9D245-1BD9-4440-8523-8956E5E3724D

P356

J.YGYNO.2008.11.027

P1433

Gynecologic Oncology

P1476

Adjuvant gemcitabine plus doce ...... esults of a prospective study.

@en

P2093

Carol A Aghajanian

http://www.w3.org/2001/XMLSchema#string

David Spriggs

http://www.w3.org/2001/XMLSchema#string

Joseph Larkin

http://www.w3.org/2001/XMLSchema#string

Martee L Hensley

http://www.w3.org/2001/XMLSchema#string

Nadeem Abu-Rustum

http://www.w3.org/2001/XMLSchema#string

Nicole Ishill

http://www.w3.org/2001/XMLSchema#string

Paul Sabbatini

http://www.w3.org/2001/XMLSchema#string

William Tew

http://www.w3.org/2001/XMLSchema#string

P304

563-567

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YGYNO.2008.11.027

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Robert A Soslow

P577

2009-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19135708

http://www.w3.org/2001/XMLSchema#string